Clinical Trials
10 trialsNCT01876043 2021-01-25
APLIPO
Institut Bergonié
Phase 2 Terminated
NCT03117361 2020-12-02
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
PharmaMar
Phase 2 Terminated
NCT00780975 2020-11-24
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
PharmaMar
Phase 2 Terminated
NCT01102426 2020-11-10
ADMYRE
PharmaMar
Phase 3 Completed
NCT03070964 2020-10-14
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
PharmaMar
Phase 2 Terminated
NCT02100657 2020-10-12
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
PharmaMar
Phase 1 Completed
NCT00780143 2018-11-09
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
PharmaMar
Phase 1/2 Terminated
NCT00884286 2018-04-25
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
PharmaMar
Phase 2 Completed
NCT00788099 2011-06-07
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
PharmaMar
Phase 1 Completed
NCT00229203 2009-12-24
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
PharmaMar
Phase 2 Completed